PK and PD Study of Oral F/TAF for HIV Prevention

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
This multi-center Phase I study is designed to characterize the PK and PD of F/TAF oral tablets to assess systemic and genital tract bioavailability in healthy women. The oral tablets to be used in the study are F/TAF (200/10 mg), F/TAF (200/25 mg) and F/TDF (200/300 mg, Truvada). Samples will be obtained before, during and after dosing in two study phases.
Epistemonikos ID: e6463239faba5f898de7391376f54b5b30311af7
First added on: May 17, 2024